Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

18.24
+0.04500.25%
Pre-market: 18.10-0.1400-0.77%07:42 EDT
Volume:2.48M
Turnover:45.32M
Market Cap:1.79B
PE:-7.04
High:18.64
Open:18.45
Low:18.02
Close:18.20
Loading ...

Sarepta suspends non-ambulatory Elevidys shipments after second death

TIPRANKS
·
15 Jun

BRIEF-Roche Provides Safety Update On Elevidys™ Gene Therapy For Duchenne Muscular Dystrophy In Non-Ambulatory Patients

Reuters
·
15 Jun

BRIEF-Sarepta Provides Safety Update For Elevidys And Initiates Steps To Strengthen Safety In Non-Ambulatory Individuals With Duchenne

Reuters
·
15 Jun

Roche Holding Ag - European Regulators Request Temporary Clinical Holds on Elevidys Studies

THOMSON REUTERS
·
15 Jun

Sarepta Therapeutics Inc - Envision Study Paused for Protocol Amendment

THOMSON REUTERS
·
15 Jun

Sarepta Therapeutics Inc - Event Reported to FDA and Global Health Authorities

THOMSON REUTERS
·
15 Jun

Sarepta Provides Safety Update for Elevidys and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals With Duchenne

THOMSON REUTERS
·
15 Jun

Sarepta Therapeutics Inc - Second Case of Acute Liver Failure Resulting in Death Reported

THOMSON REUTERS
·
15 Jun

Sarepta Therapeutics Inc - FDA Concurs With Pause in Envision Study Dosing

THOMSON REUTERS
·
15 Jun

Sarepta Therapeutics Inc - Shipments of Elevidys for Non-Ambulatory Patients Suspended

THOMSON REUTERS
·
15 Jun

Sarepta Likely to Meet Revised Guidance, Oppenheimer Says

MT Newswires Live
·
10 Jun

Barclays Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
09 Jun

Sarepta Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
07 Jun

Scotiabank Upgrades Sarepta Therapeutics to Sector Outperform From Sector Perform, $80 Price Target

MT Newswires Live
·
06 Jun

Sarepta Therapeutics Inc : Scotiabank Raises to Sector Outperform From Sector Perform

THOMSON REUTERS
·
06 Jun

Sarepta upgraded to Outperform from Sector Perform at Scotiabank

TIPRANKS
·
06 Jun

US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs

Reuters
·
06 Jun

BMO Capital Remains a Buy on Sarepta Therapeutics (SRPT)

TIPRANKS
·
06 Jun

Buy Rating on Sarepta Therapeutics Driven by FDA Platform Technology Designation

TIPRANKS
·
05 Jun

Sarepta Therapeutics Secures FDA Platform Technology Designation for rAAVrh74 Viral Vector in Gene Therapy for Limb-Girdle Muscular Dystrophy

Reuters
·
04 Jun